FDA Denies NDA for Celiprolol

Article

Acer Therapeutics Inc. announced on Tuesday they received a CRL from the FDA regarding their NDA from celiprolol (Edsivo).

FDA logo

Acer Therapeutics Inc. has announced the US Food and Drug Administration (FDA) has denied the company’s New Drug Application (NDA) for celiprolol (Edsivo) for the the treatment of vascular Ehlers-Danlos syndrome (vEDS).

Acer announced, via a press release, they had received a Complete Response Letter (CRL) from the FDA and that the CRL called for an “adequate and well-controlled” trial to determine whether celiprolol reduced the risk of clinical events in patients with vEDS.

“We remain committed to working closely with the FDA to fully understand its response,” said Chris Schelling, chief executive officer and founder of Acer. “We expect to respond to the FDA in the third quarter of this year.”

The NDA submitted by Acer was based on the results of a clinical trial that involved 53 patients who received either twice daily celiprolol orally or a placebo for up to 5 years.

Investigators from the trial found that 5 of the 25 patients (20%) receiving celiprolol experienced an arterial rupture or dissection during the study period, compared to 14 of the 28 patients (50%) in the placebo group. The combined primary and secondary endpoints of intestinal or uterine rupture affected 6 (24%) celiprolol patients and 17 (61%) in the placebo group.

In the press release, officials from Acer stated they planned to request a meeting with the FDA to discuss their response. Celiprolol is currently approved for the treatment of management of mild to moderate hypertension and effort-induced angina pectoris.

Recent Videos
Signs and Symptoms of Connective Tissue Disease
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
Saeed Mohammad, MD: IBAT Inhibitors for Cholestatic Disease
© 2024 MJH Life Sciences

All rights reserved.